Imane Alispahic

Dr. Imane Alispahic


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IAImane Alispahic
Imane Alispahic
JEJosefin Eklöf
Josefin Eklöf
Pradeesh SivapalanPradeesh Sivapalan
Pradeesh Sivapalan
AJAlexander Jordan
Alexander Jordan
Zitta F B Barrella HarboeZitta F B Barrella Harboe
Zitta F B Barrella Harboe
Jens Ulrik Stæhr JensenJens Ulrik Stæhr Jensen
Jens Ulrik Stæhr Jensen
Background: Prior research has raised concerns regarding the use of macrolides and their association with an increased risk of cardiovascular events. Methods: We conducted a cohort study, where we explored the cardiovascular risks associated with the treatment of COPD patients using macrolide antibiotics–namely azithromycin, clarithromycin, and roxithromycin—with amoxicillin serving as a reference. The study focused on COPD patients in an outpatient setting and included a thorough 3-year follow-up. Patients were categorized into four groups based on their treatment. The primary analysis utilized an adjusted Cox model, supplemented by sensitivity analysis through inverse probability of treatment weighting. Results: No significant differences were found in major adverse cardiovascular events (MACE—stroke, acute myocardial infarction, cardiovascular death) between the macrolide groups, and the amoxicillin/hazard ratios (HR) were azithromycin HR = 1.01, clarithromycin HR = 0.99, and roxithromycin HR = 1.02. Similarly, sensitivity analysis showed no disparities in all-cause mortality and cardiovascular death among the groups. Conclusions: Overall, the study revealed no evidence of increased risk of MACE, all-cause mortality, or cardiovascular death in COPD patients treated with these macrolides compared to amoxicillin over a 3-year period.

27 September 2022 in Trials
Verified
Journal Article
Open access
PDF file
JEJosefin Eklöf
Josefin Eklöf
IAImane Alispahic
Imane Alispahic
PSPradeesh Sivapalan
Pradeesh Sivapalan
TWTorgny Wilcke
Torgny Wilcke
NSNiels Seersholm
Niels Seersholm
Jens Ulrik Stæhr JensenJens Ulrik Stæhr Jensen
Jens Ulrik Stæhr Jensen
Background: Pseudomonas aeruginosa infection is seen in chronic pulmonary disease and is associated with exacerbations and poor long-term prognosis. However, evidence-based guidelines for the management and treatment of P. aeruginosa infection in chronic, non-cystic fibrosis (CF) pulmonary disease are lacking. The aim of this study is to investigate whether targeted antibiotic treatment against P. aeruginosa can reduce exacerbations and mortality in patients with chronic obstructive pulmonary disease (COPD), non-CF bronchiectasis, and asthma. Methods: This study is an ongoing multicenter, randomized, controlled, open-label trial. A total of 150 patients with COPD, non-CF bronchiectasis or asthma, and P. aeruginosa-positive lower respiratory tract samples will be randomly assigned with a 1:1 ratio to either no antibiotic treatment or anti-pseudomonal antibiotic treatment with intravenous beta-lactam and oral ciprofloxacin for 14 days. The primary outcome, analyzed with two co-primary endpoints, is (i) time to prednisolone and/or antibiotic requiring exacerbation or death, in the primary or secondary health sector, within days 20–365 from study allocation and (ii) days alive and without exacerbation within days 20–365 from the study allocation. Discussion: This trial will determine whether targeted antibiotics can benefit future patients with chronic, non-CF pulmonary disease and P. aeruginosa infection in terms of reduced morbidity and mortality, thus optimizing therapeutic approaches in this large group of chronic patients. Trial registration: ClinicalTrials.gov NCT03262142. Registered on August 25, 2017.

12 July 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
EREma Rastoder
Ema Rastoder
Pradeesh SivapalanPradeesh Sivapalan
Pradeesh Sivapalan
JEJosefin Eklöf
Josefin Eklöf
IAImane Alispahic
Imane Alispahic
AJAlexander Jordan
Alexander Jordan
Jens Ulrik Stæhr JensenJens Ulrik Stæhr Jensen
Jens Ulrik Stæhr Jensen
Patients with chronic obstructive pulmonary disease (COPD) are prone to developing arterial hypertension, and many patients are treated with the calcium channel blocker amlodipine. However, it remains unclear whether using this drug potentially affects the risk of acute severe exacerbations (AECOPD) and all-cause mortality in these patients. The data were collected from Danish national registries, containing complete information on health, prescriptions, hospital admissions, and outpatient clinic visits. The COPD patients (n = 48,488) were matched via propensity score on known predictors of the primary outcome in an active comparator design. One group was exposed to amlodipine treatment, and the other was exposed to bendroflumethiazide, since both of these drugs are considered to be the first choice for the treatment of arterial hypertension according to Danish guidelines. The use of amlodipine was associated with a reduced risk of death from all causes at the 1-year follow-up (hazard ratio 0.69, 95% confidence interval: 0.62–0.76) compared with the use of bendroflumethiazide in the matched patients. No difference in the risk of severe AECOPD was found. In the COPD patients, amlodipine use was associated with a lower risk of death from all causes compared with the use of bendroflumethiazide. Amlodipine seems to be a safe first choice for the treatment of arterial hypertension in COPD patients.

25 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
IAImane Alispahic
Imane Alispahic
JEJosefin Eklöf
Josefin Eklöf
Pradeesh SivapalanPradeesh Sivapalan
Pradeesh Sivapalan
AJAlexander Jordan
Alexander Jordan
Zitta F B Barrella HarboeZitta F B Barrella Harboe
Zitta F B Barrella Harboe
Jens Ulrik Stæhr JensenJens Ulrik Stæhr Jensen
Jens Ulrik Stæhr Jensen
Background: Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition where many patients are given antibiotics like amoxicillin and macrolides (clarithromycin, azithromycin, roxithromycin) for bacterial infections. Recent concerns about clarithromycin’s potential link to cardiovascular events have arisen, despite its effectiveness against respiratory pathogens. This study aims to compare the cardiovascular risk of macrolide antibiotics versus amoxicillin in suspected COPD patients. Method: We used the Danish National Health Service Prescription Database (DNHSP) to identify COPD patients and their use of antibiotics. The included COPD patients were divided into four groups: amoxicillin users, roxithromycin users, clarithromycin users and azithromycin users. Data from multiple registries were merged to track hospitalizations, causes of death, and major adverse cardiovascular events (MACEs) as the primary endpoint. Patients were followed for a 3-year period. We applied adjusted Cox regression and sensitivity analyses with IPTW and IPCW to address confounders and censoring. Results: Our study involved 45,869 patients who were prescribed a long-acting muscarinic antagonist, over the age of 40 years old and who received one of the following antibiotics: amoxicillin, azithromycin, clarithromycin, or roxithromycin. No increased risk of MACEs was observed in macrolide-treated patients compared to those treated with amoxicillin (azithromycin: HR 0.97: 95% CI 0.83–1.13 p = 0.69, clarithromycin: HR 1.06 95% CI 0.87–1.28 p = 0.57, roxithromycin: HR 1.04 95% CI 0.91–1.18 p = 0.60), as confirmed by the sensitivity analysis (azithromycin: HR 0.95 95% CI 0.82–1.11 p = 0.52, clarithromycin: HR 1.05 95% CI 0.87–1.27 p = 0.60, roxithromycin: HR 1.05 95% CI 0.92–1.19 p = 0.48). Similarly, hazard ratios for all-cause mortality and cardiovascular death among the antibiotic groups showed no significant statistical differences. Conclusions: These findings suggest that there is no difference in the risk of MACEs, all-cause mortality, or cardiovascular death between the amoxicillin group and the macrolide group in a large and unselected population of COPD patients.

9 September 2023 in European Respiratory Journal
Verified
Conference Paper
Closed access
IAImane Alispahic
Imane Alispahic
JEJosefin Eklof
Josefin Eklof
AJAlexander Svorre Jordan
Alexander Svorre Jordan
PSPradeesh Sivapalan
Pradeesh Sivapalan
ZHZitta Barrella Harboe
Zitta Barrella Harboe
JJJens-Ulrik Stæhr Jensen
Jens-Ulrik Stæhr Jensen
Background: Treatment with macrolide antibiotic clarithromycin in cardiovascular risk patients increases the risk of myocardial infarction and death from cardiovascular cause. Macrolides like clarithromycin, roxithromycin and especially azithromycin are frequently used worldwide for lower respiratory tract infections in COPD-patients.The objective of this study was to estimate the risk of cardiovascular events and all-cause mortality among COPD-patients treated with these three macrolides. Treatment with amoxicillin was used as a reference. Methods: Nationwide cohort study among all severely ill COPD-patients treated in outpatient clinics in our country. The Danish health registers allowed for complete follow-up for all the defined outcomes in the 3-year follow-up period. We have divided out study population into four groups:amoxicillin, azithromycin, clarithromycin and roxithromycin. The main analysis was an adjusted cox proportional hazard model. As a sensitivity analysis, we used the inverse probability of treatment weighting method. Results: The primary outcome, which was major adverse cardiovascular events defined as stroke or acute myocardial infarction, we found no statistical differences between the groups in the adjusted cox proportional hazard regression analysis for the main COPD population (azithromycin: HR=1.01, CI95% 0.77-1.32, P value=0.96; clarithromycin: HR=0.92, 95%CI 0.65-1.32, Pvalue=0.66; roxithromycin:HR=0.91, CI95% 0.73-1.15, P value=0.45). The IPTW sensitivity analysis confirmed the findings in the main analysis. Conclusions: We found no differences between the antibiotics for MACE.